{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:30:56Z","timestamp":1791685856583,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82301420"],"award-info":[{"award-number":["No.82301420"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82301663"],"award-info":[{"award-number":["No.82301663"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["No.2025A1515010666"],"award-info":[{"award-number":["No.2025A1515010666"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"State Key Laboratory of Neurology and Oncology Drug Development","award":["No. SKLSIM-20250174"],"award-info":[{"award-number":["No. SKLSIM-20250174"]}]},{"name":"Leading Innovation Specialist Support Program of Guangdong Province","award":["No.0820250119"],"award-info":[{"award-number":["No.0820250119"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Long-term levodopa treatment for Parkinson\u2019s disease (PD) is often complicated by motor fluctuations and dyskinesia. Predictive biomarkers for these debilitating side effects are currently lacking, hindering personalized treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to characterize the cerebrospinal fluid (CSF) metabolome across the PD continuum, distinguish disease-related from medication-related changes, and identify predictive biomarkers for levodopa-induced motor complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed targeted CSF metabolomic data from the Parkinson\u2019s Progression Markers Initiative (PPMI) cohort, which included healthy controls, prodromal, and PD participants. Statistical analyses revealed differentially abundant metabolites. The association of the metabolite dopamine 3-O-sulfate (DA3S) with motor complications was assessed using logistic regression and decision tree models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>DA3S was the most significantly altered metabolite in PD patients, with its elevation exclusively driven by levodopa treatment. DA3S levels were strongly correlated with levodopa exposure (LEDD) and demonstrated a significant independent association with the development of motor complications. A multivariable model combining DA3S, disease duration, and LEDD was used to predict motor complications, with an AUC of 0.806. A decision tree further confirmed the value of DA3S for risk stratification in specific patient subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CSF DA3S is a pharmacodynamic marker of central levodopa metabolism and a robust, independent predictor of the onset of motor complications in PD patients. When combined with clinical variables, it facilitates effective risk stratification, providing a novel tool for personalizing therapy to mitigate treatment-related adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-07761-7","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:04:09Z","timestamp":1769627049000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cerebrospinal fluid dopamine 3-O-sulfate as a novel biomarker for predicting motor complications in Parkinson\u2019s disease: insights from the PPMI cohort"],"prefix":"10.1186","volume":"24","author":[{"given":"Jieshan","family":"Chi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siming","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengfei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3492-4669","authenticated-orcid":false,"given":"Yuhu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"7761_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","volume":"403","author":"HR Morris","year":"2024","unstructured":"Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. The pathogenesis of parkinson\u2019s disease. Lancet. 2024;403:293\u2013304.","journal-title":"Lancet"},{"key":"7761_CR2","doi-asserted-by":"publisher","first-page":"478","DOI":"10.4103\/1673-5374.350193","volume":"18","author":"J Rodriguez-Pallares","year":"2023","unstructured":"Rodriguez-Pallares J, Garcia-Garrote M, Parga JA, Labandeira-Garcia JL. Combined cell-based therapy strategies for the treatment of parkinson\u2019s disease: focus on mesenchymal stromal cells. Neural Regen Res. 2023;18:478\u201384.","journal-title":"Neural Regen Res"},{"key":"7761_CR3","doi-asserted-by":"publisher","first-page":"105491","DOI":"10.1016\/j.nbd.2021.105491","volume":"159","author":"V Iyer","year":"2021","unstructured":"Iyer V, Venkiteswaran K, Savaliya S, Lieu CA, Handly E, Gilmour TP, Kunselman AR, Subramanian T. The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias. Neurobiol Dis. 2021;159:105491.","journal-title":"Neurobiol Dis"},{"key":"7761_CR4","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s13311-020-00889-4","volume":"17","author":"SD Aradi","year":"2020","unstructured":"Aradi SD, Hauser RA. Medical management and prevention of motor complications in parkinson\u2019s disease. Neurotherapeutics. 2020;17:1339\u201365.","journal-title":"Neurotherapeutics"},{"key":"7761_CR5","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40265-022-01747-7","volume":"82","author":"DG Di Luca","year":"2022","unstructured":"Di Luca DG, Reyes NGD, Fox SH. Newly approved and investigational drugs for motor symptom control in parkinson\u2019s disease. Drugs. 2022;82:1027\u201353.","journal-title":"Drugs"},{"key":"7761_CR6","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1212\/WNL.0000000000012246","volume":"97","author":"F Bove","year":"2021","unstructured":"Bove F, Mulas D, Cavallieri F, Castrioto A, Chabardes S, Meoni S, Schmitt E, Bichon A, Di Stasio E, Kistner A, et al. Long-term outcomes (15 Years) after subthalamic nucleus deep brain stimulation in patients with Parkinson disease. Neurology. 2021;97:e254\u201362.","journal-title":"Neurology"},{"key":"7761_CR7","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41531-025-01126-5","volume":"11","author":"J Gervasoni","year":"2025","unstructured":"Gervasoni J, Marino C, Imarisio A, Santucci L, Napolitano E, Nuzzo T, Yahyavi I, Avenali M, Cicchinelli M, Buongarzone G, et al. Independent serum metabolomics approaches identify disrupted glutamic acid and Serine metabolism in parkinson\u2019s disease patients. NPJ Parkinsons Dis. 2025;11:274.","journal-title":"NPJ Parkinsons Dis"},{"key":"7761_CR8","doi-asserted-by":"crossref","unstructured":"Chang KH, Cheng ML, Tang HY, Huang CY, Wu HC, Chen CM. Alterations of sphingolipid and phospholipid pathways and ornithine level in the plasma as biomarkers of Parkinson\u2019s disease. Cells 2022;11.","DOI":"10.3390\/cells11030395"},{"key":"7761_CR9","doi-asserted-by":"crossref","unstructured":"Flores-Torres MH, Peng X, Jeanfavre S, Clish C, Wang Y, McCullough ML, Healy B, Schwarzschild MA, Bjornevik K, Ascherio A. Plasma metabolomics profiles in prodromal and clinical Parkinson\u2019s disease. Mov Disord. 2025;40:2209\u20132219.","DOI":"10.1002\/mds.30308"},{"key":"7761_CR10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41531-024-00713-2","volume":"10","author":"W Hu","year":"2024","unstructured":"Hu W, Wang W, Liao H, Bulloch G, Zhang X, Shang X, Huang Y, Hu Y, Yu H, Yang X, et al. Metabolic profiling reveals Circulating biomarkers associated with incident and prevalent parkinson\u2019s disease. NPJ Parkinsons Dis. 2024;10:130.","journal-title":"NPJ Parkinsons Dis"},{"key":"7761_CR11","doi-asserted-by":"publisher","first-page":"eadp7063","DOI":"10.1126\/sciadv.adp7063","volume":"11","author":"A Balck","year":"2025","unstructured":"Balck A, Borsche M, Campbell P, Luo X, Harvey J, Bruckmann T, Ludwig C, Harms A, Lohmann K, Brown E, et al. The role of dopaminergic medication and specific pathway alterations in idiopathic and PRKN\/PINK1-mediated parkinson\u2019s disease. Sci Adv. 2025;11:eadp7063.","journal-title":"Sci Adv"},{"key":"7761_CR12","doi-asserted-by":"publisher","first-page":"106698","DOI":"10.1016\/j.nbd.2024.106698","volume":"202","author":"F Carrillo","year":"2024","unstructured":"Carrillo F, Palomba NP, Ghirimoldi M, Dido C, Fortunato G, Khoso S, Giloni T, Santilli M, Bocci T, Priori A, et al. Multiomics approach discloses lipids and metabolites profiles associated to parkinson\u2019s disease stages and applied therapies. Neurobiol Dis. 2024;202:106698.","journal-title":"Neurobiol Dis"},{"key":"7761_CR13","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/mds.28608","volume":"36","author":"T Kremer","year":"2021","unstructured":"Kremer T, Taylor KI, Siebourg-Polster J, Gerken T, Staempfli A, Czech C, Dukart J, Galasko D, Foroud T, Chahine LM, et al. Longitudinal analysis of multiple neurotransmitter metabolites in cerebrospinal fluid in early parkinson\u2019s disease. Mov Disord. 2021;36:1972\u20138.","journal-title":"Mov Disord"},{"key":"7761_CR14","doi-asserted-by":"publisher","first-page":"103390","DOI":"10.1016\/j.jaut.2025.103390","volume":"152","author":"C Noelker","year":"2025","unstructured":"Noelker C, Seitz F, Sturn A, Neff F, Andrei-Selmer LC, Rau L, Geyer A, Ross JA, Bacher M, Dodel R. Autoantibodies against alpha-synuclein inhibit its aggregation and cytotoxicity. J Autoimmun. 2025;152:103390.","journal-title":"J Autoimmun"},{"key":"7761_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12974-024-03218-0","volume":"21","author":"C Otto","year":"2024","unstructured":"Otto C, Kalantzis R, Kubler-Weller D, Kuhn AA, Bold T, Regler A, Strathmeyer S, Wittmann J, Ruprecht K, Heelemann S. Comprehensive analysis of the cerebrospinal fluid and serum metabolome in neurological diseases. J Neuroinflammation. 2024;21:234.","journal-title":"J Neuroinflammation"},{"key":"7761_CR16","first-page":"100963","volume":"19","author":"K Liang","year":"2024","unstructured":"Liang K, Yang L, Kang J, Liu B, Zhang D, Wang L, Wang W, Wang Q. Improving treatment for parkinson\u2019s disease: Harnessing photothermal and phagocytosis-driven delivery of Levodopa nanocarriers across the blood-brain barrier. Asian J Pharm Sci. 2024;19:100963.","journal-title":"Asian J Pharm Sci"},{"key":"7761_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41419-024-06763-x","volume":"15","author":"A Masato","year":"2024","unstructured":"Masato A, Andolfo A, Favetta G, Bellini EN, Cogo S, Dalla Valle L, Boassa D, Greggio E, Plotegher N, Bubacco L. Sequestosome-1 (SQSTM1\/p62) as a target in dopamine catabolite-mediated cellular dyshomeostasis. Cell Death Dis. 2024;15:424.","journal-title":"Cell Death Dis"},{"key":"7761_CR18","doi-asserted-by":"publisher","first-page":"105429","DOI":"10.1016\/j.nbd.2021.105429","volume":"157","author":"L Andreoli","year":"2021","unstructured":"Andreoli L, Abbaszadeh M, Cao X, Cenci MA. Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism. Neurobiol Dis. 2021;157:105429.","journal-title":"Neurobiol Dis"},{"key":"7761_CR19","doi-asserted-by":"publisher","first-page":"464597","DOI":"10.1016\/j.chroma.2023.464597","volume":"1715","author":"AM King","year":"2024","unstructured":"King AM, Wilson ID, Plumb RS, Gethings LA, Trengove R, Maker G. The rapid separation and characterization of sulfates of tyrosine and its metabolites in reaction mixtures and human urine using a Cyclic ion mobility device and mass spectrometry. J Chromatogr A. 2024;1715:464597.","journal-title":"J Chromatogr A"},{"key":"7761_CR20","doi-asserted-by":"publisher","first-page":"nwab163","DOI":"10.1093\/nsr\/nwab163","volume":"9","author":"B Chen","year":"2022","unstructured":"Chen B, Tong X, Zhang X, Gui W, Ai G, Huang L, Ding D, Zhang J, Kang L. Sulfation modification of dopamine in brain regulates aggregative behavior of animals. Natl Sci Rev. 2022;9:nwab163.","journal-title":"Natl Sci Rev"},{"key":"7761_CR21","doi-asserted-by":"publisher","first-page":"127031","DOI":"10.1016\/j.envpol.2025.127031","volume":"384","author":"G Fedorova","year":"2025","unstructured":"Fedorova G, Grabic R, Kapukotuwa GR, Galicova P, Stanova AV. Quantitative analysis of neurotransmitters in fish brain: A tool to assess neurochemical effects of psychoactive pollutants. Environ Pollut. 2025;384:127031.","journal-title":"Environ Pollut"},{"key":"7761_CR22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.pediatrneurol.2017.06.014","volume":"75","author":"KL Pappan","year":"2017","unstructured":"Pappan KL, Kennedy AD, Magoulas PL, Hanchard NA, Sun Q, Elsea SH. Clinical metabolomics to segregate aromatic amino acid decarboxylase deficiency from Drug-Induced metabolite elevations. Pediatr Neurol. 2017;75:66\u201372.","journal-title":"Pediatr Neurol"},{"key":"7761_CR23","doi-asserted-by":"publisher","first-page":"136084","DOI":"10.1016\/j.foodchem.2023.136084","volume":"420","author":"Z Guo","year":"2023","unstructured":"Guo Z, Liu Y, Xiang J, Liang X. Mechanochemical Preparation of red clover extract\/beta-cyclodextrin dispersion: enhanced water solubility and activities in alleviating high-fat diet-induced lipid accumulation and gut microbiota dysbiosis in mice. Food Chem. 2023;420:136084.","journal-title":"Food Chem"},{"key":"7761_CR24","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.ijbiomac.2022.12.247","volume":"228","author":"J Zheng","year":"2023","unstructured":"Zheng J, Cheng Y, Bao M, Li Z, Lu X, Shan Y. Ultrasound improves the thermal stability and binding capacity of ovomucin by promoting the dissociation of insoluble ovomucin aggregates. Int J Biol Macromol. 2023;228:478\u201386.","journal-title":"Int J Biol Macromol"},{"key":"7761_CR25","doi-asserted-by":"publisher","first-page":"e2501206","DOI":"10.1002\/smll.202501206","volume":"21","author":"T Mallick","year":"2025","unstructured":"Mallick T, Mondal A, Das S, De P. Inhibition of insulin amyloid fibrillogenesis using antioxidant copolymers with dopamine pendants. Small. 2025;21:e2501206.","journal-title":"Small"},{"key":"7761_CR26","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.actbio.2021.12.010","volume":"140","author":"S Samanta","year":"2022","unstructured":"Samanta S, Yla-Outinen L, Rangasami VK, Narkilahti S, Oommen OP. Bidirectional cell-matrix interaction dictates neuronal network formation in a brain-mimetic 3D scaffold. Acta Biomater. 2022;140:314\u201323.","journal-title":"Acta Biomater"},{"key":"7761_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13024-023-00694-5","volume":"18","author":"KC Paul","year":"2023","unstructured":"Paul KC, Zhang K, Walker DI, Sinsheimer J, Yu Y, Kusters C, Del Rosario I, Folle AD, Keener AM, Bronstein J, et al. Untargeted serum metabolomics reveals novel metabolite associations and disruptions in amino acid and lipid metabolism in parkinson\u2019s disease. Mol Neurodegener. 2023;18:100.","journal-title":"Mol Neurodegener"},{"key":"7761_CR28","doi-asserted-by":"crossref","unstructured":"Fridjonsdottir E, Shariatgorji R, Nilsson A, Vallianatou T, Odell LR, Schembri LS, Svenningsson P, Fernagut PO, Crossman AR, Bezard E, Andren PE. Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia. Sci Adv. 2021;7.","DOI":"10.1126\/sciadv.abe5948"},{"key":"7761_CR29","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.neuron.2018.01.017","volume":"97","author":"AE Girasole","year":"2018","unstructured":"Girasole AE, Lum MY, Nathaniel D, Bair-Marshall CJ, Guenthner CJ, Luo L, Kreitzer AC, Nelson AB. A subpopulation of striatal neurons mediates Levodopa-Induced dyskinesia. Neuron. 2018;97:787\u2013e795786.","journal-title":"Neuron"},{"key":"7761_CR30","doi-asserted-by":"publisher","first-page":"101566","DOI":"10.1016\/j.xcrm.2024.101566","volume":"5","author":"C Shen","year":"2024","unstructured":"Shen C, Shen B, Liu D, Han L, Zou K, Gan L, Ren J, Wu B, Tang Y, Zhao J, et al. Bidirectional regulation of levodopa-induced dyskinesia by a specific neural ensemble in globus pallidus external segment. Cell Rep Med. 2024;5:101566.","journal-title":"Cell Rep Med"},{"key":"7761_CR31","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1126\/science.aam9080","volume":"357","author":"LF Burbulla","year":"2017","unstructured":"Burbulla LF, Song P, Mazzulli JR, Zampese E, Wong YC, Jeon S, Santos DP, Blanz J, Obermaier CD, Strojny C, et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in parkinson\u2019s disease. Science. 2017;357:1255\u201361.","journal-title":"Science"},{"key":"7761_CR32","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41586-022-05407-4","volume":"611","author":"L Ma","year":"2022","unstructured":"Ma L, Day-Cooney J, Benavides OJ, Muniak MA, Qin M, Ding JB, Mao T, Zhong H. Locomotion activates PKA through dopamine and adenosine in striatal neurons. Nature. 2022;611:762\u20138.","journal-title":"Nature"},{"key":"7761_CR33","doi-asserted-by":"publisher","first-page":"105922","DOI":"10.1016\/j.neubiorev.2024.105922","volume":"167","author":"J Rusz","year":"2024","unstructured":"Rusz J, Krack P, Tripoliti E. From prodromal stages to clinical trials: the promise of digital speech biomarkers in parkinson\u2019s disease. Neurosci Biobehav Rev. 2024;167:105922.","journal-title":"Neurosci Biobehav Rev"},{"key":"7761_CR34","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1002\/mds.29520","volume":"38","author":"A ZhuParris","year":"2023","unstructured":"ZhuParris A, Thijssen E, Elzinga WO, Makai-Boloni S, Kraaij W, Groeneveld GJ, Doll RJ. Treatment detection and movement disorder Society-Unified parkinson\u2019s disease rating Scale, part III Estimation using finger tapping tasks. Mov Disord. 2023;38:1795\u2013805.","journal-title":"Mov Disord"},{"key":"7761_CR35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00401-024-02706-0","volume":"147","author":"J Rutledge","year":"2024","unstructured":"Rutledge J, Lehallier B, Zarifkar P, Losada PM, Shahid-Besanti M, Western D, Gorijala P, Ryman S, Yutsis M, Deutsch GK, et al. Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early parkinson\u2019s disease. Acta Neuropathol. 2024;147:52.","journal-title":"Acta Neuropathol"},{"key":"7761_CR36","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41531-021-00261-z","volume":"7","author":"J Zhou","year":"2021","unstructured":"Zhou J, Li J, Papaneri AB, Kobzar NP, Cui G. Dopamine neuron challenge test for early detection of parkinson\u2019s disease. NPJ Parkinsons Dis. 2021;7:116.","journal-title":"NPJ Parkinsons Dis"},{"key":"7761_CR37","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/mds.29193","volume":"37","author":"JJ Ferreira","year":"2022","unstructured":"Ferreira JJ, Poewe W, Rascol O, Stocchi F, Antonini A, Moreira J, Guimaraes B, Rocha JF, Soares-da-Silva P. Effect of Opicapone on Levodopa pharmacokinetics in patients with fluctuating parkinson\u2019s disease. Mov Disord. 2022;37:2272\u201383.","journal-title":"Mov Disord"},{"key":"7761_CR38","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40263-021-00888-9","volume":"36","author":"M Fabbri","year":"2022","unstructured":"Fabbri M, Ferreira JJ, Rascol O. COMT inhibitors in the management of parkinson\u2019s disease. CNS Drugs. 2022;36:261\u201382.","journal-title":"CNS Drugs"},{"key":"7761_CR39","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41531-025-01133-6","volume":"11","author":"J Perron","year":"2025","unstructured":"Perron J, Krak S, Booth S, Zhang D, Ko JH. Cerebral perfusion imaging predicts levodopa-induced dyskinesia in parkinsonian rat model. NPJ Parkinsons Dis. 2025;11:278.","journal-title":"NPJ Parkinsons Dis"},{"key":"7761_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41531-022-00277-z","volume":"8","author":"F Stocchi","year":"2022","unstructured":"Stocchi F, Antonini A, Berg D, Bergmans B, Jost W, Katzenschlager R, Kulisevsky J, Odin P, Valldeoriola F, Ray Chaudhuri K. Safinamide in the treatment pathway of parkinson\u2019s disease: a European Delphi consensus. NPJ Parkinsons Dis. 2022;8:17.","journal-title":"NPJ Parkinsons Dis"},{"key":"7761_CR41","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/brain\/awaa394","volume":"144","author":"YM Kehnemouyi","year":"2021","unstructured":"Kehnemouyi YM, Wilkins KB, Anidi CM, Anderson RW, Afzal MF, Bronte-Stewart HM. Modulation of beta bursts in subthalamic sensorimotor circuits predicts improvement in bradykinesia. Brain. 2021;144:473\u201386.","journal-title":"Brain"},{"key":"7761_CR42","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1093\/brain\/awad004","volume":"146","author":"C Chu","year":"2023","unstructured":"Chu C, Liu S, He N, Zeng Z, Wang J, Zhang Z, Zeljic K, van der Stelt O, Sun B, Yan F, et al. Subthalamic stimulation modulates motor network in parkinson\u2019s disease: recover, relieve and remodel. Brain. 2023;146:2780\u201391.","journal-title":"Brain"},{"key":"7761_CR43","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/mds.23068","volume":"25","author":"S Ku","year":"2010","unstructured":"Ku S, Glass GA. Age of parkinson\u2019s disease onset as a predictor for the development of dyskinesia. Mov Disord. 2010;25:1177\u201382.","journal-title":"Mov Disord"},{"key":"7761_CR44","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/mds.29796","volume":"39","author":"HL Frequin","year":"2024","unstructured":"Frequin HL, Verschuur CVM, Suwijn SR, Boel JA, Post B, Bloem BR, van Hilten JJ, van Laar T, Tissingh G, Munts AG, et al. Long-Term Follow-Up of the LEAP study: early versus delayed Levodopa in early parkinson\u2019s disease. Mov Disord. 2024;39:975\u201382.","journal-title":"Mov Disord"},{"key":"7761_CR45","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/s42003-024-06330-2","volume":"7","author":"G Cheng","year":"2024","unstructured":"Cheng G, Hardy M, Hillard CJ, Feix JB, Kalyanaraman B. Mitigating gut microbial degradation of Levodopa and enhancing brain dopamine: implications in parkinson\u2019s disease. Commun Biol. 2024;7:668.","journal-title":"Commun Biol"},{"key":"7761_CR46","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41531-025-00954-9","volume":"11","author":"JJ Yun","year":"2025","unstructured":"Yun JJ, Abulikemu S, Jangwanich KL, Tai YF, Haar S. Modulatory effect of Levodopa on the basal ganglia-cerebellum connectivity in parkinson\u2019s disease. NPJ Parkinsons Dis. 2025;11:115.","journal-title":"NPJ Parkinsons Dis"},{"key":"7761_CR47","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s40263-020-00769-7","volume":"34","author":"D Urso","year":"2020","unstructured":"Urso D, Chaudhuri KR, Qamar MA, Jenner P. Improving the delivery of Levodopa in parkinson\u2019s disease: A review of approved and emerging therapies. CNS Drugs. 2020;34:1149\u201363.","journal-title":"CNS Drugs"},{"key":"7761_CR48","doi-asserted-by":"crossref","unstructured":"Giampaoli O, Ieno C, Sciubba F, Spagnoli M, Miccheli A, Tomassini A, Aureli W, Fattorini L. Metabolic biomarkers of red beetroot juice intake at rest and after physical exercise. Nutrients. 2023;15.","DOI":"10.3390\/nu15092026"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07761-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07761-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07761-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:17:00Z","timestamp":1781630220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07761-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7761"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07761-7","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"23 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Parkinson\u2019s Progression Markers Initiative (PPMI) study was approved by the institutional review board of all the participating sites. All participants provided written informed consent before enrollment in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The data analysis performed in this study adhered to the PPMI Data and Publications Committee (DPC) guidelines and was formally reviewed by the DPC.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"178"}}